Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1774 + Fulvestrant in ER+/HER2- Advanced Breast Cancer
NCT05986071Phase 2Not yet recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvusertib in breast cancer, sponsored by Institut Paoli-Calmettes. Planned start May 2024; status: not yet recruiting.
02
Drugs
tuvusertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05986071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986071.